DE4222459C2 - 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten - Google Patents

3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten

Info

Publication number
DE4222459C2
DE4222459C2 DE4222459A DE4222459A DE4222459C2 DE 4222459 C2 DE4222459 C2 DE 4222459C2 DE 4222459 A DE4222459 A DE 4222459A DE 4222459 A DE4222459 A DE 4222459A DE 4222459 C2 DE4222459 C2 DE 4222459C2
Authority
DE
Germany
Prior art keywords
spiro
undecane
furyl
hydroxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE4222459A
Other languages
German (de)
English (en)
Other versions
DE4222459A1 (de
Inventor
Marco Frigerio
Patrizia Ferrari
Piero Melloni
Giuliana Salani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority to DE4222459A priority Critical patent/DE4222459C2/de
Priority to DK93110193.5T priority patent/DK0578080T3/da
Priority to AT93110193T priority patent/ATE152107T1/de
Priority to ES93110193T priority patent/ES2100397T3/es
Priority to DE59306238T priority patent/DE59306238D1/de
Priority to EP93110193A priority patent/EP0578080B1/en
Priority to US08/082,372 priority patent/US5444082A/en
Priority to JP5168890A priority patent/JPH06239785A/ja
Publication of DE4222459A1 publication Critical patent/DE4222459A1/de
Application granted granted Critical
Publication of DE4222459C2 publication Critical patent/DE4222459C2/de
Priority to GR970401238T priority patent/GR3023595T3/el
Priority to HK98104926A priority patent/HK1005869A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/36—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/50—Spiro compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE4222459A 1992-07-08 1992-07-08 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten Expired - Fee Related DE4222459C2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE4222459A DE4222459C2 (de) 1992-07-08 1992-07-08 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
AT93110193T ATE152107T1 (de) 1992-07-08 1993-06-25 3,9-disubstituierte-spiro (5.5)undecane mit cardiovasculaire wirkung, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate
ES93110193T ES2100397T3 (es) 1992-07-08 1993-06-25 Espiro(5.5)undecanos 3,9-disubstituidos activos sobre el sistema cardiovascular, proceso para su preparacion y composicion farmaceutica que contiene los mismos.
DE59306238T DE59306238D1 (de) 1992-07-08 1993-06-25 3,9-Disubstituierte-spiro (5.5)undecane mit cardiovasculaire Wirkung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
EP93110193A EP0578080B1 (en) 1992-07-08 1993-06-25 3,9-disubstituted-spiro (5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same
DK93110193.5T DK0578080T3 (da) 1992-07-08 1993-06-25 3,9-disubstituerede spiro 5.5 undecaner med aktivitet på det cardiovaskulære system, fremgangsmåde til fremstilling af disse og farmaceutisk præparat indeholdende disse
US08/082,372 US5444082A (en) 1992-07-08 1993-06-28 3,9-disubstituted-spiro(5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same
JP5168890A JPH06239785A (ja) 1992-07-08 1993-07-08 ３，９−二置換スピロ［５．５］ウンデカン類の活性、製造および医薬組成物
GR970401238T GR3023595T3 (en) 1992-07-08 1997-05-30 3,9-disubstituted-spiro (5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same
HK98104926A HK1005869A1 (en) 1992-07-08 1998-06-05 3,9-disubstituted-spiro (5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4222459A DE4222459C2 (de) 1992-07-08 1992-07-08 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten

Publications (2)

Publication Number Publication Date
DE4222459A1 DE4222459A1 (de) 1994-01-13
DE4222459C2 true DE4222459C2 (de) 1995-09-14

Family

ID=6462775

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4222459A Expired - Fee Related DE4222459C2 (de) 1992-07-08 1992-07-08 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
DE59306238T Expired - Fee Related DE59306238D1 (de) 1992-07-08 1993-06-25 3,9-Disubstituierte-spiro (5.5)undecane mit cardiovasculaire Wirkung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59306238T Expired - Fee Related DE59306238D1 (de) 1992-07-08 1993-06-25 3,9-Disubstituierte-spiro (5.5)undecane mit cardiovasculaire Wirkung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate

Country Status (9)

Country Link
US (1) US5444082A (cg-RX-API-DMAC7.html)
EP (1) EP0578080B1 (cg-RX-API-DMAC7.html)
JP (1) JPH06239785A (cg-RX-API-DMAC7.html)
AT (1) ATE152107T1 (cg-RX-API-DMAC7.html)
DE (2) DE4222459C2 (cg-RX-API-DMAC7.html)
DK (1) DK0578080T3 (cg-RX-API-DMAC7.html)
ES (1) ES2100397T3 (cg-RX-API-DMAC7.html)
GR (1) GR3023595T3 (cg-RX-API-DMAC7.html)
HK (1) HK1005869A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870538B1 (fr) * 2004-05-19 2006-07-14 Servier Lab Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP7006990B2 (ja) 2017-11-17 2022-02-10 セリックス バイオ プライヴェート リミテッド 眼障害の処置のための組成物及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256277A (en) * 1966-06-14 Azaspiro alkanes
BE788490A (fr) * 1971-09-08 1973-01-02 Geschickter Fund Med Res Azaspiranes substitues par du silicium ou du germanium, leur preparation et compositions pharmaceutiques les contenant
US4098823A (en) * 1976-02-11 1978-07-04 Miles Laboratories, Inc. Monospiroalkyl derivatives of prostaglandins
US4737503A (en) * 1986-10-08 1988-04-12 Vipont Laboratories, Inc. Method for inhibiting the release of histamine
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5234922A (en) * 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea

Also Published As

Publication number Publication date
EP0578080B1 (en) 1997-04-23
ES2100397T3 (es) 1997-06-16
DK0578080T3 (da) 1997-07-21
US5444082A (en) 1995-08-22
DE59306238D1 (de) 1997-05-28
HK1005869A1 (en) 1999-01-29
JPH06239785A (ja) 1994-08-30
DE4222459A1 (de) 1994-01-13
EP0578080A2 (en) 1994-01-12
ATE152107T1 (de) 1997-05-15
GR3023595T3 (en) 1997-08-29
EP0578080A3 (cg-RX-API-DMAC7.html) 1994-04-13

Similar Documents

Publication Publication Date Title
EP0307342B1 (de) 3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte
EP0354495A1 (de) Alkoxy-4 (1H)-pyridon-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE69204627T2 (de) Prostaglandine.
EP1773801A1 (de) Verfahren zur gewinnung von reinem tetrahydrocannabinol
DD156369A5 (de) Herstellung von rechtsdrehenden 5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3b]-indolen
DE19633349A1 (de) Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
DE4222459C2 (de) 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
DE4227616A1 (de) 17-(3-Furyl) und 17-4(Pyridazinyl)-5beta, 14beta-androstanderivate, die auf das kardiovaskuläre System wirken, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die dieselben enthalten
DE69414602T2 (de) Sterin epoxid verbindungen zur krebsbehandlung
HK1005869B (en) 3,9-disubstituted-spiro (5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same
EP0202529B1 (de) Neue Phenolderivate, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen und Arzneimittel
CH622777A5 (cg-RX-API-DMAC7.html)
DE4040685A1 (de) 3-(n-methyl-n-alkyl)amino-2-methoxymethylenpropan-1-ol-derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische zusammensetzungen
DE4221635C1 (de) 3beta-Digitoxigenin- und 3beta-Dihydrodigitoxigenin-Derivate
DE2409675A1 (de) Alpha-alkyl(oder -aryl)-thio-5-hydroxytryptophan-derivat und verfahren zu seiner herstellung
EP0019059B1 (de) Verfahren zur Herstellung von Cholestenderivaten und neue Zwischenprodukte in deren Herstellung
DE4232656C2 (de) Cyclopentanperhydrophenanthren-17-furyl-3ß-derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutischen Zusammensetzungen
DE4221501C1 (de) Cyclopentanperhydrophenanthren-17µ-(3- furyl)-3-alkyl-/alkylidenderivate
DE69603793T2 (de) Kardioaktive 17-Hydroxyiminoalkyl- und 17-Hydroxyiminomethylalkenyl-Steroid-Derivate, ein Verfahren zu ihrer Herstellung und pharmazeutische Präparate davon
EP0003212A1 (de) 2.4-Diamino-5-benzylpyrimidine und diese enthaltende pharmazeutische Präparate sowie deren Herstellung
EP0208200A1 (de) Phenylessigsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahen zu ihrer Herstellung
DE3006708A1 (de) Thromboxananaloge und thromboxanzwischenprodukte
DE2653604C2 (cg-RX-API-DMAC7.html)
Meese et al. Dimethyl 3, 3, 4, 4,. 5,. 5, 6, 6‐(2H8)‐6‐methoxycarbonyl‐2‐oxo‐hexanephosphonate, a versatile reagent for the synthesis of deuterated ω‐carboxy prostanoids
DE2401763A1 (de) Optisch aktive hydroxyenone

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee